Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017 Summary According to the recently published report 'Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017'; Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocandus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression. The report 'Muscarinic Acetylcholine Receptor M2 (CHRM2) - Pipeline Review, H1 2017' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology and Genetic Disorders which include indications Alzheimer's Disease, Overactive Bladder, Depression, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Axillary Hyperhidrosis, Cognitive Disorders, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Rett Syndrome, Schizophrenia, Stroke and Urinary Incontinence. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2) - The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects - The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development Allergan Plc Anavex Life Sciences Corp FemmePharma Global Healthcare Inc Juniper Pharmaceuticals Inc Karuna Pharmaceuticals Inc TheraVida Inc Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles (ANAVEX-273 + donepezil hydrochloride) - Drug Profile Product Description Mechanism Of Action R&D Progress (oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile Product Description Mechanism Of Action R&D Progress (oxybutynin chloride + rivastigmine) - Drug Profile Product Description Mechanism Of Action R&D Progress (trospium chloride + xanomeline tartrate) - Drug Profile Product Description Mechanism Of Action R&D Progress ANAVEX-141 - Drug Profile Product Description Mechanism Of Action R&D Progress ANAVEX-273 - Drug Profile Product Description Mechanism Of Action R&D Progress oxybutynin chloride - Drug Profile Product Description Mechanism Of Action R&D Progress oxybutynin chloride - Drug Profile Product Description Mechanism Of Action R&D Progress oxybutynin chloride ER - Drug Profile Product Description Mechanism Of Action R&D Progress THVD-201 - Drug Profile Product Description Mechanism Of Action R&D Progress Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones Featured News & Press Releases May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017 Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer's Disease Patients Nov 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer's Disease Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis Sep 28, 2016: Anavex Compound to be Tested in Biogen Neurological Protection Model Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson's Disease Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016 Jul 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016 Jul 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016 Jul 12, 2016: Anavex to Present at the Alzheimer's Association International Conference (AAIC) 2016 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Allergan Plc, H1 2017 Pipeline by Anavex Life Sciences Corp, H1 2017 Pipeline by FemmePharma Global Healthcare Inc, H1 2017 Pipeline by Juniper Pharmaceuticals Inc, H1 2017 Pipeline by Karuna Pharmaceuticals Inc, H1 2017 Pipeline by TheraVida Inc, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
